Literature DB >> 24304875

Signalling: a new target for p53-null tumours.

Isabel Lokody.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24304875     DOI： 10.1038/nrc3651

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  1 in total

1.  Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors.

Authors:  Brooke M Emerling; Jonathan B Hurov; George Poulogiannis; Kazumi S Tsukazawa; Rayman Choo-Wing; Gerburg M Wulf; Eric L Bell; Hye-Seok Shim; Katja A Lamia; Lucia E Rameh; Gary Bellinger; Atsuo T Sasaki; John M Asara; Xin Yuan; Andrea Bullock; Gina M Denicola; Jiaxi Song; Victoria Brown; Sabina Signoretti; Lewis C Cantley
Journal:  Cell       Date:  2013-11-07       Impact factor: 41.582
  1 in total
  3 in total

1.  Synthetic Lethality Is a Novel and Potential Paradigm for Precision Medicine in Advanced Hepatocellular Carcinoma.

Authors:  Mingyu Chen; Xiujun Cai
Journal:  Liver Cancer       Date:  2019-11-07       Impact factor: 11.740

Review 2.  Molecularly targeted therapies for p53-mutant cancers.

Authors:  Dekuang Zhao; William M Tahaney; Abhijit Mazumdar; Michelle I Savage; Powel H Brown
Journal:  Cell Mol Life Sci       Date:  2017-06-22       Impact factor: 9.261

3.  Expressions of Topo IIα and Ki67 in breast cancer and its clinicopathologic features and prognosis.

Authors:  Guangyu Sun; Shuyan Wang; Ying Wang
Journal:  Pak J Med Sci       Date:  2019       Impact factor: 1.088
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.